Abstract: The invention provides agents that promote or inhibit neurite elongation comprising as an active ingredient an antibody that recognizes a varicella-zoster virus immediate-early protein and cross-reacts with a brain-derived neurotrophic factor. The invention also provides methods of utilizing such agents to prevent or treat a nervous disease or a disease with nerve hypersensitivity caused by a condition selected from the group consisting of postherpetic neuralgia, chronic pains, experience-dependent social aversion and stress.

Abstract: The present invention relates to a therapeutic agent for neuropathic pain containing, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable acid addition salt thereof: (wherein R1, R2, R3, R4, R5, R6, R7, R8, A, and B have the same definitions as those described in the specification), and an animal model produced by administering (+)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octohydro-trans-quinolino[2,3-g]isoquinoline. The present invention makes it possible to perform drug treatment for neuropathic pain. The therapeutic effect of a compound against neuropathic pain can also be evaluated.

Abstract: An antibody library is prepared by selecting a light chain variable region capable of binding to the variable region of heavy chain to reproduce an active conformation and using the same. Because of being capable of maintaining the diversity of the heavy chain variable region at a high ratio in vitro, the antibody library of the present invention is expected as enabling the acquisition of antibodies with various binding activities.

Abstract: An interleukin-6 suppressive agent comprising lactoperoxidase as an active ingredient is used as a pharmaceutical preparation or the like for prevention and/or therapy of a disease caused by production of interleukin-6, such as thrombocytosis, myeloma, Castleman syndrome, rheumatoid arthritis, or influenza-virus infectious disease.

Abstract: The invention provides agents that promote or inhibit neurite elongation comprising as an active ingredient an antibody that recognizes a varicella-zoster virus immediate-early protein and cross-reacts with a brain-derived neurotrophic factor. The invention also provides methods of utilizing such agents to prevent or treat a nervous disease or a disease with nerve hypersensitivity caused by a condition selected from the group consisting of postherpetic neuralgia, chronic pains, experience-dependent social aversion and stress.

Abstract: An interleukin-6 suppressive agent comprising lactoperoxidase as an active ingredient is used as a pharmaceutical preparation or the like for prevention and/or therapy of a disease caused by production of interleukin-6, such as thrombocytosis, myeloma, Castleman syndrome, rheumatoid arthritis, or influenza-virus infectious disease.

Abstract: An interleukin-6 suppressive agent comprising lactoperoxidase as an active ingredient is used as a pharmaceutical preparation or the like for prevention and/or therapy of a disease caused by production of interleukin-6, such as thrombocytosis, myeloma, Castleman syndrome, rheumatoid arthritis, or influenza-virus infectious disease.

Abstract: The present invention relates to a therapeutic agent for neuropathic pain containing, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable acid addition salt thereof: (wherein R1, R2, R3, R4, R5, R6, R7, R8, A, and B have the same definitions as those described in the specification), and an animal model produced by administering (+)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octohydro-trans-quinolino[2,3-g]isoquinoline. The present invention makes it possible to perform drug treatment for neuropathic pain. The therapeutic effect of a compound against neuropathic pain can also be evaluated.

Abstract: An interleukin-6 suppressive agent comprising lactoperoxidase as an active ingredient is used as a pharmaceutical preparation or the like for prevention and/or therapy of a disease caused by production of interleukin-6, such as thrombocytosis, myeloma, Castleman syndrome, rheumatoid arthritis, or influenza-virus infectious disease.

Abstract: The present invention provides a recombinant varicella-zoster virus prepared by inserting, into the viral genome, nucleic acids from the hepatitis B virus genome, a genomic DNA of the recombinant varicella-zoster virus, a live vaccine containing the recombinant varicella-zoster virus as an effective ingredient, an antigen derived from the recombinant varicella-zoster virus, and diagnostic agent containing the antigen.The recombinant varicella-zoster virus of the present invention can be utilized as a multivalent vaccine having an excellent immunity effect both on chicken pox and hepatitis B, and expression products and genomic DNA thereof may be used as a multivalent diagnostic agent.

Abstract: The present invention provides a recombinant varicella-zoster virus prepared by inserting into the viral genome, nucleic acids from hepatitis B virus genome, a genomic DNA of the recombinant varicella-zoster virus, a live vaccine containing the recombinant varicella-zoster virus as an effective ingredient, an antigen derived from the recombinant varicella-zoster virus, and diagnostic agent containing the antigen. The recombinant varicella-zoster virus of the present invention can be utilized as a multivalent vaccine having an excellent immunity effect both on chickenpox and hepatitis B, and the expression products and genomic DNA thereof may be used as a multivalent diagnostic agent.

Abstract: Antiviral agent containing a crude drug effective on a broad range of viruses.